160 related articles for article (PubMed ID: 1943491)
1. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on human gut mucosa.
Gebhard RL; Ewing SL; Schlasner LA; Hunninghake DB; Prigge WF
Lipids; 1991 Jul; 26(7):492-4. PubMed ID: 1943491
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
3. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors.
Krasovec M; Elsner P; Burg G
Dermatology; 1993; 186(4):248-52. PubMed ID: 8513188
[TBL] [Abstract][Full Text] [Related]
4. Long-term clinical tolerance of lovastatin and simvastatin.
Bilheimer DW
Cardiology; 1990; 77 Suppl 4():58-65. PubMed ID: 2073673
[TBL] [Abstract][Full Text] [Related]
5. Intestinal HMG-CoA reductase activity is low in hypercholesterolemic patients and is further decreased with lovastatin therapy.
Freeman ML; Prigge WF; Hunninghake DB; Duane WC; Gebhard RL
J Lipid Res; 1988 Jul; 29(7):839-45. PubMed ID: 3411244
[TBL] [Abstract][Full Text] [Related]
6. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK
Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672
[TBL] [Abstract][Full Text] [Related]
7. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
Alberts AW
Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
[TBL] [Abstract][Full Text] [Related]
9. Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity in the rat ileum: effects of bile acids and lovastatin.
Nguyen LB; Shefer S; Salen G; Ness GC; Batta A; Chowdhary IR; Paroulek E; Hauser S
Metabolism; 1994 Nov; 43(11):1446-50. PubMed ID: 7968602
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
11. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
12. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
13. A 6-month trial of simvastatin (HMG-CoA reductase inhibitor) in the treatment of hypercholesterolaemia.
Steyn K; Weich HF; Vermaak WJ; Marais AD; Omar MA; Van Gelder AL; Fourie J; Kotze TJ; Stander I; Firth JC
S Afr Med J; 1991 Jun; 79(11):639-45. PubMed ID: 2047945
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients.
Lansberg PJ; Mitchel YB; Shapiro D; Kastelein JJ; Altman R; Jerums G; Bolzano K; Giannini S; Davignon J; DeWailly P
Atherosclerosis; 1995 Aug; 116(2):153-62. PubMed ID: 7575771
[TBL] [Abstract][Full Text] [Related]
15. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
Illingworth DR; Bacon S
Am J Cardiol; 1987 Oct; 60(12):33G-42G. PubMed ID: 3314447
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia.
Barth JD; Kruisbrink OA; Van Dijk AL
BMJ; 1990 Sep; 301(6753):669. PubMed ID: 2224231
[No Abstract] [Full Text] [Related]
17. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin.
Chao Y; Chen JS; Hunt VM; Kuron GW; Karkas JD; Liou R; Alberts AW
Eur J Clin Pharmacol; 1991; 40 Suppl 1():S11-4. PubMed ID: 2044637
[TBL] [Abstract][Full Text] [Related]
18. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin and the human lens. Clinical results of a 3-year follow-up.
Behrens-Baumann W; Thiery J; Wieland E; Fieseler HG; Seidel D
Arzneimittelforschung; 1992 Aug; 42(8):1023-4. PubMed ID: 1418074
[TBL] [Abstract][Full Text] [Related]
19. Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms.
Owens D; Collins P; Johnson A; Tighe O; Robinson K; Tomkin GH
Biochim Biophys Acta; 1991 Apr; 1082(3):303-9. PubMed ID: 1903069
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
Slater EE; MacDonald JS
Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
